Theralase
Manufacturing · Canada · 11-50 Employees
View Company Info for Free
Overview
Headquarters
41 Hollinger Rd, Toronto, Ontario, M4B 3...Phone Number
(416) 699-5273Website
theralase.comRevenue
<$5 MillionStock Symbol
TLTIndustry
ZI Rank: 1
Signal Type
Dec
Jan
Feb
Mar
Apr
May
ZI Rank
2
2
1
1
1
1
About Theralase
Theralase Technologies is a Canadian clinical stage pharmaceutical company focused on the research and development of light-activated therapies for the treatment of cancer and other diseases. The company combines therapeutic laser technology with photodynamic compounds to develop innovative, non-invasive treatment approaches. Through its commitment to scientific advancement and patient care, Theralase aims to improve quality of life and bring new hope to individuals affected by cancer.Explore more
Theralase Org Chart
DG
President, World Trade
Get the full picture
Sign in to uncover key details.
Sell smarter with deeper company insights.
ZoomInfo gives you access to real-time firmographics, buying signals, org charts, and decision-makers - helping your GTM teams prioritize accounts, personalize outreach with AI-driven automation, and close deals faster.
Is Theralase your ideal customer? 
Let us give you the heads up on whether it's a good time to reach out
Theralase, which may be a good buyer, showed buying intent in Masked Content Topic
Check out if Theralase is spiking on competitors!
Click to see if Theralase had a recent Job posting/layoffs
Earning: See what the market has to say on Theralase recently announced quarterly report
Funding: Get notified immidiatlly once Theralase has new funding data
Competitive Alert! Recent activity has been detected by your competitor Masked Content
Congratulate Masked Content for being promoted to Masked Content at Theralase
Website visits: Recent activity has been detected on your website
Product Launch: Get notified when Theralase launches new products
Check if Theralase has recently received funding, and reach out quickly before it becomes old news!
Recommended Actions
Reach out to Masked Content who joined Theralase as Masked Content
Find 2 more new buyers
Compare Similar Companies to Theralase
Compare insights from companies similar to Theralase, focusing on performance, financial data, growth rates, and unique benchmarks to identify key industry trends and opportunities.
Revenue
Number of Employees
Type
Funding
Founded In
$6.5M
11-50
Private
-
1989
Kipton LadeExecutive (CEO and Chief Operating Officer and President and Owner)
Company Profile Activity
Activity Insights
Theralase is experiencing very low activity levels compared to other companies in the Manufacturing sector.
What does this means?
Theralase is drawing exceptional interest within the Manufacturing industry, suggesting notable developments or strong market momentum, learn more about Theralase.
Theralase financials insights
Gather financial insights about Theralase, including details on funding rounds, investors, total funding, and acquisitions, to gain a comprehensive understanding of their financial strategy.
2022
Share Placement
$2.5M
2024
Share Placement
$390K
2025
Stock/Share Issuance
$488K
2026
Private Equity
$110K
Theralase Tech Stack
A closer look at the technologies used by Theralase
Most Recent Scoops
Project
Theralase has announced that its Phase Two clinical study regulatory approval provides the ability to generate significant revenues in Canada and the United States from sales of its bladder cancer treatment technology to healthcare practitioners, hospitals, and institutions. The approval also creates opportunities to generate capital from licensing or acquisition of the technology by larger pharmaceutical companies for various geographic regions.
Partnership, Pharmaceuticals, Business Finance, Clinical Operations, Finance
Project
Theralase has announced that its Ruvidar has demonstrated 10-year shelf life at room temperature, offering significant logistical and cost advantages for global distribution compared to competitors' biologically proposed solutions that require complex drug preparation and administration along with expensive and time-consuming negative 80 degrees cold storage management.
Product Development, Logistics / Supply Chain, Pharmaceuticals
Project
Theralase has announced that its next milestones include enrolling and treating the remaining two patients by the end of 2025, completing follow-up on all patients until study completion in Q1 2027, completing soft and hard data lock by Q1 2027, and submitting a new drug application to Health Canada and the FDA for marketing approval in early 2027. Marketing approval is expected in six months if priority review is obtained, or in 10 months if not.
Compliance, Medical Research, Pharmaceuticals, Clinical Operations
Project
Theralase has announced that its Ruvidar delivers high complete response rates with an ultra-high safety profile using a single intravesical treatment, with no direct related serious adverse events directly related to Ruvidar or the laser system that activates it. This differentiates it significantly from other more expensive and complex multi-dose immunotherapeutic approaches.
Product Development, Medical Research, Pharmaceuticals, Clinical Operations
Project
Safety, Medical Research, Pharmaceuticals, Clinical Operations, Health & Safety
Theralase News & Media
Theralase Raises C$2.66 Million to Advance Bladder Cancer Drug Programs
Tipranks Press Release.Theralase Technologies Inc. announced that it has received CAD 0.672627 million in funding
Theralase Technologies Inc announced that it has completed a non brokered private placement and issued 3,363,134 Units at a price of CAD 0.2 per unit for aggregate gross proceeds of CAD 672,626.8 on... -July 28, 2025 at 09:50 am EDT - MarketScreenerTheralase Technologies Inc. (TLTFF) Q3 2024 Earnings Call Transcript
Theralase Technologies Inc. (OTCQX:TLTFF) Q3 2024 Earnings Conference Call December 4, 2024 11:00 AM ETCompany ParticipantsMatthew Perraton - Chairman of...
Read more news
Top Manufacturing Companies
Top companies in New Zealand by revenue
Top companies in United Kingdom by revenue
Frequently Asked Questions Regarding Theralase
Sign Up For FreeTo access detailed company insights
Theralase Technologies is a Canadian clinical stage pharmaceutical company focused on the research and development of light-activated therapies for the treatment of cancer and other diseases. The company combines therapeutic laser technology with photodynamic compounds to develop innovative, non-invasive treatment approaches. Through its commitment... Read More
